Trans-activating mutations of the pseudokinase ERBB3

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Trans-activating mutations of the pseudokinase ERBB3 ; volume:43 ; number:29 ; day:28 ; month:5 ; year:2024 ; pages:2253-2265 ; date:7.2024
Oncogene ; 43, Heft 29 (28.5.2024), 2253-2265, 7.2024

Creator: Koivu, Marika K. A.
Chakroborty, Deepankar
Airenne, Tomi T.
Johnson, Mark S.
Kurppa, Kari J.
Elenius, Klaus

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41388-024-03070-9

URN: urn:nbn:de:101:1-2409292103381.695609311187

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Koivu, Marika K. A.
Chakroborty, Deepankar
Airenne, Tomi T.
Johnson, Mark S.
Kurppa, Kari J.
Elenius, Klaus
SpringerLink (Online service)

Other Objects (12)

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Akten

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Akten

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Akten

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Trans-activating mutations of the pseudokinase ERBB3

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Activating FGFR1 Mutations in Sporadic Pheochromocytomas

Somatic activating mutations in MAP2K1 cause melorheostosis

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Point mutations M2-trans-membrane Torpedo

E‐cadherin can limit the transforming properties of activating β‐catenin mutations

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations

Novel mutatıons and diverse clinical phenotypes in recombınase-activating gene 1 deficiency

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder

Related objects

Reset password